title: [Orthotopic heart transplantation: clinical experience on 56 patients].
abstract: OBJECTIVE
  To summarize the clinical experience on 56 patients undergoing orthotopic heart transplantation.
  
  
  METHODS
  Between May 2000 and December 2003 56 patients, 47 with cardiomyopathy, 2 with end-stage valvular heart disease, 2 with end-stage ischemic heart disease, 2 with primary malignant cardiac tumor, 1 with complicated congenital heart disease, 1 with muscular dystrophy cardiomyopathy, and 1 with refractory malignant ventricular arrhythmias, underwent orthotopic heart transplantation in the Transplantation Center of Fudan University. The operative procedures included 19 conventional Stanford orthotopic cardiac transplantation in 19 cases and bicaval anastomotic cardiac transplantation in 37 cases. Postoperatively, the patients were prescribed with cyclosporine A + corticosteroids + MMF or FK506 + corticosteroids + MMF as anti-rejection therapy.
  
  
  RESULTS
  One patient undergoing his fifth operation died of bleeding 3 days after operation. All survivors were followed-up for 12.4 months on average. Five patients died within 1 year postoperatively with a one-year survival rate of 91%. One patient died of allograft vasculopathy 38 months after operation. Other patients enjoyed heart function recovering to class I-II (NYHA).
  
  
  CONCLUSIONS
  With proper recipient selection, excellent donor heart conservation, bicaval anastomotic technique, and efficient postoperative surveillance and treatment, heart transplantion may produce satisfying mid-term results.
authors.affiliation: Department of Cardiothoracic Surgery, Zhongshan Hospital of Fudan University, Shanghai Institute of Cardiovascular Diseases, Transplantation Center of Fudan University, Shanghai 200032, China.
authors.forename: Chun-sheng
authors.initials: CS
authors.lastname: Wang
authors.forename: Hao
authors.initials: H
authors.lastname: Chen
authors.forename: Tao
authors.initials: T
authors.lastname: Hong
authors.forename: Qiang
authors.initials: Q
authors.lastname: Zhao
authors.forename: Wen-jun
authors.initials: WJ
authors.lastname: Ding
authors.forename: Yi-qing
authors.initials: YQ
authors.lastname: Wang
authors.forename: Kai
authors.initials: K
authors.lastname: Song
authors.forename: Hao
authors.initials: H
authors.lastname: Lai
authors.forename: Dong
authors.initials: D
authors.lastname: Zhao
authors.forename: Shou-guo
authors.initials: SG
authors.lastname: Yang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002311:Cardiomyopathy, Dilated / Q000601:surgery*; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival; D016027:Heart Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015996:Survival Rate
chemical_list: D007166:Immunosuppressive Agents